{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:20:31Z","timestamp":1790036431120,"version":"4.0.1"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10495-026-02281-7","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:15:16Z","timestamp":1771604116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method"],"prefix":"10.1007","volume":"31","author":[{"given":"Abhiroop","family":"Sengupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasmita","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritama","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab K.","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda S.","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2281_CR1","doi-asserted-by":"publisher","first-page":"205520762110489","DOI":"10.1177\/20552076211048979","volume":"7","author":"DM Harmon","year":"2021","unstructured":"Harmon DM, Young CD, Bear MA et al (2021) Integrating online community support into outpatient breast cancer care: Mayo clinic connect online platform. Digit Health 7:20552076211048979 https:\/\/doi.org\/10.1177\/20552076211048979","journal-title":"Digit Health"},{"key":"2281_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"2281_CR3","doi-asserted-by":"publisher","first-page":"e01848","DOI":"10.1016\/j.sciaf.2023.e01848","volume":"21","author":"EN Manson","year":"2023","unstructured":"Manson EN, Achel DG (2023) Fighting breast cancer in low-and-middle-income countries \u2013 What must we do to get every woman screened on regular basis? Sci Afr 21:e01848. https:\/\/doi.org\/10.1016\/j.sciaf.2023.e01848","journal-title":"Sci Afr"},{"key":"2281_CR4","doi-asserted-by":"publisher","first-page":"101505","DOI":"10.1016\/j.jddst.2020.101505","volume":"56","author":"U Hani","year":"2020","unstructured":"Hani U, Rahamathulla M, Osmani RA et al (2020) Recent advances in novel drug delivery systems and approaches for management of breast cancer: A comprehensive review. J Drug Deliv Sci Technol 56:101505. https:\/\/doi.org\/10.1016\/j.jddst.2020.101505","journal-title":"J Drug Deliv Sci Technol"},{"key":"2281_CR5","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s11845-022-02926-x","volume":"191","author":"D Courtney","year":"2022","unstructured":"Courtney D, Davey MG, Moloney BM et al (2022) Breast cancer recurrence: factors impacting occurrence and survival. Ir J Med Sci (1971) 191:2501\u20132510. https:\/\/doi.org\/10.1007\/s11845-022-02926-x","journal-title":"Ir J Med Sci (1971)"},{"key":"2281_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bib\/bbv072","volume":"17","author":"AS Datta","year":"2016","unstructured":"Datta AS, Biswas S (2016) Comparison of haplotype-based statistical tests for disease association with rare and common variants. Brief Bioinform 17:657\u2013671. https:\/\/doi.org\/10.1093\/bib\/bbv072","journal-title":"Brief Bioinform"},{"key":"2281_CR7","doi-asserted-by":"publisher","unstructured":"Gopinath A, Cheema AH, Chaludiya K et al (2022) The impact of dietary fat on breast cancer incidence and survival: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.30003","DOI":"10.7759\/cureus.30003"},{"key":"2281_CR8","unstructured":"Joseph S (2024) The relationship between diet and cancer: exploring the impact of food choices on cancer risk and prevention. J Cancer Epidemiol Prev 9"},{"key":"2281_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/epirev\/mxt010","volume":"36","author":"MF Munsell","year":"2014","unstructured":"Munsell MF, Sprague BL, Berry DA et al (2014) Body mass index and breast cancer risk according to postmenopausal Estrogen-Progestin use and hormone receptor status. Epidemiol Rev 36:114\u2013136. https:\/\/doi.org\/10.1093\/epirev\/mxt010","journal-title":"Epidemiol Rev"},{"key":"2281_CR10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.32846","volume":"147","author":"L Rainey","year":"2020","unstructured":"Rainey L, Eriksson M, Trinh T et al (2020) The impact of alcohol consumption and physical activity on breast cancer: the role of breast cancer risk. Int J Cancer 147:931\u2013939. https:\/\/doi.org\/10.1002\/ijc.32846","journal-title":"Int J Cancer"},{"key":"2281_CR11","doi-asserted-by":"publisher","first-page":"e1919615","DOI":"10.1001\/jamanetworkopen.2019.19615","volume":"3","author":"CR Langton","year":"2020","unstructured":"Langton CR, Whitcomb BW, Purdue-Smithe AC et al (2020) Association of parity and breastfeeding with risk of early natural menopause. JAMA Netw Open 3:e1919615. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.19615","journal-title":"JAMA Netw Open"},{"key":"2281_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/rg.210109","volume":"42","author":"Y Gao","year":"2022","unstructured":"Gao Y, Samreen N, Heller SL (2022) Non- BRCA Early-Onset breast cancer in young women. Radiographics 42:5\u201322. https:\/\/doi.org\/10.1148\/rg.210109","journal-title":"Radiographics"},{"key":"2281_CR13","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1001\/jama.2024.18575","volume":"332","author":"LS M\u00f8rch","year":"2024","unstructured":"M\u00f8rch LS, Meaidi A, Corn G et al (2024) Breast cancer in users of Levonorgestrel-Releasing intrauterine systems. JAMA 332:1578. https:\/\/doi.org\/10.1001\/jama.2024.18575","journal-title":"JAMA"},{"key":"2281_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G et al (2022) Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol 40:1529\u20131541. https:\/\/doi.org\/10.1200\/JCO.21.02112","journal-title":"J Clin Oncol"},{"key":"2281_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3896","volume":"15","author":"EC Dietze","year":"2015","unstructured":"Dietze EC, Sistrunk C, Miranda-Carboni G et al (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15:248\u2013254. https:\/\/doi.org\/10.1038\/nrc3896","journal-title":"Nat Rev Cancer"},{"key":"2281_CR16","doi-asserted-by":"publisher","unstructured":"Shen L, Zhang S, Wang K, Wang X (2021) Familial breast cancer: disease related gene mutations and screening strategies for Chinese population. Front Oncol 11:740227 https:\/\/doi.org\/10.3389\/fonc.2021.740227","DOI":"10.3389\/fonc.2021.740227"},{"key":"2281_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12253-018-00569-x","volume":"26","author":"T Deli","year":"2020","unstructured":"Deli T, Orosz M, Jakab A (2020) Hormone replacement therapy in cancer Survivors \u2013 Review of the literature. Pathol Oncol Res 26:63\u201378. https:\/\/doi.org\/10.1007\/s12253-018-00569-x","journal-title":"Pathol Oncol Res"},{"key":"2281_CR18","doi-asserted-by":"publisher","unstructured":"Alnaim L, Althiban A, Alrohaimi M (2019) Practice patterns for oral chemotherapy at different cancer centers in Riyadh, Saudi arabia: A multicenter observational study. Indian J Pharm Sci 81. https:\/\/doi.org\/10.36468\/pharmaceutical-sciences.613","DOI":"10.36468\/pharmaceutical-sciences.613"},{"key":"2281_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16:71. https:\/\/doi.org\/10.1186\/s12951-018-0392-8","journal-title":"J Nanobiotechnol"},{"key":"2281_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s11095-006-9223-y","volume":"24","author":"D Sutton","year":"2007","unstructured":"Sutton D, Nasongkla N, Blanco E, Gao J (2007) Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 24:1029\u20131046. https:\/\/doi.org\/10.1007\/s11095-006-9223-y","journal-title":"Pharm Res"},{"key":"2281_CR21","doi-asserted-by":"crossref","unstructured":"Dave RV, Mann GB (2019) Breast assessment and benign breast disease. In: Textbook of Surgery. Wiley, pp 307\u2013316","DOI":"10.1002\/9781119468189.ch35"},{"key":"2281_CR22","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I (2021) The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127:3029\u20133030. https:\/\/doi.org\/10.1002\/cncr.33587","journal-title":"Cancer"},{"key":"2281_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10585-024-10288-0","volume":"41","author":"SP Leong","year":"2024","unstructured":"Leong SP, Witte MH (2024) Cancer metastasis through the lymphatic versus blood vessels. Clin Exp Metastasis 41:387\u2013402. https:\/\/doi.org\/10.1007\/s10585-024-10288-0","journal-title":"Clin Exp Metastasis"},{"key":"2281_CR24","unstructured":"Petrucelli N, Daly MB, Pal T (1993) BRCA1- and BRCA2-Associated. Hereditary Breast and Ovarian Cancer"},{"key":"2281_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/genes15020219","volume":"15","author":"V Barili","year":"2024","unstructured":"Barili V, Ambrosini E, Bortesi B et al (2024) Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes (Basel) 15:219. https:\/\/doi.org\/10.3390\/genes15020219","journal-title":"Genes (Basel)"},{"key":"2281_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40487-019-00105-0","volume":"8","author":"J Luveta","year":"2020","unstructured":"Luveta J, Parks RM, Heery DM et al (2020) Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol Ther 8:1\u201311. https:\/\/doi.org\/10.1007\/s40487-019-00105-0","journal-title":"Oncol Ther"},{"key":"2281_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12964-021-00745-8","volume":"19","author":"C Zhao","year":"2021","unstructured":"Zhao C, Wang B, Liu E, Zhang Z (2021) Correction to: Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma. Cell Communication Signal 19:52. https:\/\/doi.org\/10.1186\/s12964-021-00745-8","journal-title":"Cell Communication Signal"},{"key":"2281_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2019.05.025","volume":"459","author":"Z Cao","year":"2019","unstructured":"Cao Z, Liao Q, Su M et al (2019) AKT and ERK dual inhibitors: the way forward? Cancer Lett 459:30\u201340. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.025","journal-title":"Cancer Lett"},{"key":"2281_CR29","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z (2020) Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun 11:5120. https:\/\/doi.org\/10.1038\/s41467-020-18794-x","journal-title":"Nat Commun"},{"key":"2281_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"2281_CR31","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014","journal-title":"J Clin Invest"},{"key":"2281_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2281_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jconrel.2020.07.003","volume":"326","author":"V Jain","year":"2020","unstructured":"Jain V, Kumar H, Anod HV et al (2020) A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Controlled Release 326:628\u2013647. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.003","journal-title":"J Controlled Release"},{"key":"2281_CR34","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE et al (2022) Subtypes of Breast cancer. Breast cancer. Exon, pp 31\u201342","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"key":"2281_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s11671-024-03985-y","volume":"19","author":"N Dasari","year":"2024","unstructured":"Dasari N, Guntuku GS, Pindiprolu SKSS (2024) Targeting triple negative breast cancer stem cells using nanocarriers. Discover Nano 19:41. https:\/\/doi.org\/10.1186\/s11671-024-03985-y","journal-title":"Discover Nano"},{"key":"2281_CR36","doi-asserted-by":"publisher","first-page":"10068","DOI":"10.3390\/ijms231710068","volume":"23","author":"A Chaudhuri","year":"2022","unstructured":"Chaudhuri A, Kumar DN, Shaik RA et al (2022) Lipid-Based nanoparticles as a pivotal delivery approach in triple negative breast cancer (TNBC) therapy. Int J Mol Sci 23:10068. https:\/\/doi.org\/10.3390\/ijms231710068","journal-title":"Int J Mol Sci"},{"key":"2281_CR37","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.1021\/acsomega.9b04006","volume":"5","author":"A Datta","year":"2020","unstructured":"Datta A, Mishra S, Manna K et al (2020) Pro-Oxidant therapeutic activities of cerium oxide nanoparticles in colorectal carcinoma cells. ACS Omega 5:9714\u20139723. https:\/\/doi.org\/10.1021\/acsomega.9b04006","journal-title":"ACS Omega"},{"key":"2281_CR38","doi-asserted-by":"publisher","first-page":"1214489","DOI":"10.3389\/fmolb.2023.1214489","volume":"10","author":"PK Tiwari","year":"2023","unstructured":"Tiwari PK, Ko T-H, Dubey R et al (2023) CRISPR\/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics. Front Mol Biosci 10:1214489. https:\/\/doi.org\/10.3389\/fmolb.2023.1214489","journal-title":"Front Mol Biosci"},{"key":"2281_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/pharmaceutics15010246","volume":"15","author":"R Pradhan","year":"2023","unstructured":"Pradhan R, Dey A, Taliyan R et al (2023) Recent advances in targeted nanocarriers for the management of triple negative breast cancer. Pharmaceutics 15:246. https:\/\/doi.org\/10.3390\/pharmaceutics15010246","journal-title":"Pharmaceutics"},{"key":"2281_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nrm2510","volume":"9","author":"H Hochegger","year":"2008","unstructured":"Hochegger H, Takeda S, Hunt T (2008) Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol 9:910\u2013916. https:\/\/doi.org\/10.1038\/nrm2510","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2281_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s43556-022-00071-6","volume":"3","author":"R Yang","year":"2022","unstructured":"Yang R, Li Y, Wang H et al (2022) Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed 3:8. https:\/\/doi.org\/10.1186\/s43556-022-00071-6","journal-title":"Mol Biomed"},{"key":"2281_CR42","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/ijc.32020","volume":"145","author":"K Pandey","year":"2019","unstructured":"Pandey K, An H, Kim SK et al (2019) Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: A review. Int J Cancer 145:1179\u20131188. https:\/\/doi.org\/10.1002\/ijc.32020","journal-title":"Int J Cancer"},{"key":"2281_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003373","author":"JP K\u00f6sters","year":"2003","unstructured":"K\u00f6sters JP, G\u00f8tzsche PC (2003) Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Reviews 2010. https:\/\/doi.org\/10.1002\/14651858.CD003373","journal-title":"Cochrane Database Syst Reviews 2010"},{"key":"2281_CR44","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics13050723","volume":"13","author":"A Bhushan","year":"2021","unstructured":"Bhushan A, Gonsalves A, Menon JU (2021) Current state of breast cancer Diagnosis, Treatment, and theranostics. Pharmaceutics 13:723. https:\/\/doi.org\/10.3390\/pharmaceutics13050723","journal-title":"Pharmaceutics"},{"key":"2281_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s43055-020-00210-5","volume":"51","author":"MAA Algazzar","year":"2020","unstructured":"Algazzar MAA, Elsayed EE-M, Alhanafy AM, Mousa WA (2020) Breast cancer imaging features as a predictor of the hormonal receptor status, HER2neu expression and molecular subtype. Egypt J Radiol Nuclear Med 51:93. https:\/\/doi.org\/10.1186\/s43055-020-00210-5","journal-title":"Egypt J Radiol Nuclear Med"},{"key":"2281_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0","journal-title":"Nat Rev Drug Discov"},{"key":"2281_CR47","doi-asserted-by":"publisher","first-page":"003685042412280","DOI":"10.1177\/00368504241228076","volume":"107","author":"J Lai","year":"2024","unstructured":"Lai J, Luo Z, Chen L, Wu Z (2024) Advances in nanotechnology-based targeted-contrast agents for computed tomography and magnetic resonance. Sci Prog 107:00368504241228076 https:\/\/doi.org\/10.1177\/00368504241228076","journal-title":"Sci Prog"},{"key":"2281_CR48","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1056\/NEJMra0901217","volume":"361","author":"RS Hotchkiss","year":"2009","unstructured":"Hotchkiss RS, Strasser A, McDunn JE, Swanson PE (2009) Cell death. N Engl J Med 361:1570\u20131583. https:\/\/doi.org\/10.1056\/NEJMra0901217","journal-title":"N Engl J Med"},{"key":"2281_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drup.2010.04.002","volume":"13","author":"SM Schleicher","year":"2010","unstructured":"Schleicher SM, Moretti L, Varki V, Lu B (2010) Progress in the unraveling of the Endoplasmic reticulum stress\/autophagy pathway and cancer: implications for future therapeutic approaches. Drug Resist Updates 13:79\u201386. https:\/\/doi.org\/10.1016\/j.drup.2010.04.002","journal-title":"Drug Resist Updates"},{"key":"2281_CR50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17:395\u2013417. https:\/\/doi.org\/10.1038\/s41571-020-0341-y","journal-title":"Nat Rev Clin Oncol"},{"key":"2281_CR51","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","volume":"12","author":"S Qian","year":"2022","unstructured":"Qian S, Wei Z, Yang W et al (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol 12:985363. https:\/\/doi.org\/10.3389\/fonc.2022.985363","journal-title":"Front Oncol"},{"key":"2281_CR52","doi-asserted-by":"crossref","unstructured":"Paoluzzi L, O\u2019Connor OA (2010) Targeting survival pathways in lymphoma","DOI":"10.1007\/978-1-4419-6706-0_5"},{"key":"2281_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X et al (2024) NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther 9:53. https:\/\/doi.org\/10.1038\/s41392-024-01757-9","journal-title":"Signal Transduct Target Ther"},{"key":"2281_CR54","doi-asserted-by":"publisher","first-page":"e0302063","DOI":"10.1371\/journal.pone.0302063","volume":"19","author":"D lv","year":"2024","unstructured":"lv D, Zhang K, Zhu C et al (2024) Predictive value of CD86 for the occurrence of sepsis (Sepsis-3) in patients with infection. PLoS ONE 19:e0302063. https:\/\/doi.org\/10.1371\/journal.pone.0302063","journal-title":"PLoS ONE"},{"key":"2281_CR55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41420-023-01766-7","volume":"9","author":"M Cao","year":"2023","unstructured":"Cao M, Wang G, Xie J (2023) Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discov 9:465. https:\/\/doi.org\/10.1038\/s41420-023-01766-7","journal-title":"Cell Death Discov"},{"key":"2281_CR56","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso PM (2016) Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J Clin Oncol 34:3803\u20133815. https:\/\/doi.org\/10.1200\/JCO.2014.59.0018","journal-title":"J Clin Oncol"},{"key":"2281_CR57","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2174\/0113895575270904231129062137","volume":"24","author":"AK Wani","year":"2024","unstructured":"Wani AK, Singh R, Akhtar N et al (2024) Targeted Inhibition of the PI3K\/Akt\/mTOR signaling axis: potential for sarcoma therapy. Mini-Reviews Med Chem 24:1496\u20131520. https:\/\/doi.org\/10.2174\/0113895575270904231129062137","journal-title":"Mini-Reviews Med Chem"},{"key":"2281_CR58","doi-asserted-by":"publisher","unstructured":"PengY, Wang Y, Zhou C et al (2022) PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol 12:819128. https:\/\/doi.org\/10.3389\/fonc.2022.819128","DOI":"10.3389\/fonc.2022.819128"},{"key":"2281_CR59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu D, Totan A, Stanescu-Spinu I-I et al (2020) PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci 22:173. https:\/\/doi.org\/10.3390\/ijms22010173","journal-title":"Int J Mol Sci"},{"key":"2281_CR60","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.3390\/cells11162508","volume":"11","author":"K Zhu","year":"2022","unstructured":"Zhu K, Wu Y, He P et al (2022) PI3K\/AKT\/mTOR-Targeted therapy for breast cancer. Cells 11:2508. https:\/\/doi.org\/10.3390\/cells11162508","journal-title":"Cells"},{"key":"2281_CR61","doi-asserted-by":"publisher","unstructured":"Tian X, Srinivasan PR, Tajiknia V et al (2024) Targeting apoptotic pathways for cancer therapy. J Clin Invest 134. https:\/\/doi.org\/10.1172\/JCI179570","DOI":"10.1172\/JCI179570"},{"key":"2281_CR62","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q et al (2024) Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther 31:1283\u20131291. https:\/\/doi.org\/10.1038\/s41417-024-00747-x","journal-title":"Cancer Gene Ther"},{"key":"2281_CR63","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","volume":"30","author":"A Strasser","year":"2009","unstructured":"Strasser A, Jost PJ, Nagata S (2009) The many roles of FAS receptor signaling in the immune system. Immunity 30:180\u2013192. https:\/\/doi.org\/10.1016\/j.immuni.2009.01.001","journal-title":"Immunity"},{"key":"2281_CR64","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.3390\/cancers15102752","volume":"15","author":"JM Pimentel","year":"2023","unstructured":"Pimentel JM, Zhou J-Y, Wu GS (2023) The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers (Basel) 15:2752. https:\/\/doi.org\/10.3390\/cancers15102752","journal-title":"Cancers (Basel)"},{"key":"2281_CR65","doi-asserted-by":"publisher","first-page":"102980","DOI":"10.1016\/j.ctrv.2025.102980","volume":"139","author":"F Giugliano","year":"2025","unstructured":"Giugliano F, De Angelis C, Pistilli B et al (2025) Overcoming resistance to CDK4\/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: innovative combinations and emerging strategies. Cancer Treat Rev 139:102980. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102980","journal-title":"Cancer Treat Rev"},{"key":"2281_CR66","doi-asserted-by":"publisher","first-page":"8488","DOI":"10.3390\/ijms24108488","volume":"24","author":"M Cejuela","year":"2023","unstructured":"Cejuela M, Gil-Torralvo A, Castilla M\u00c1 et al (2023) Abemaciclib, Palbociclib, and ribociclib in Real-World data: A direct comparison of First-Line treatment for Endocrine-Receptor-Positive metastatic breast cancer. Int J Mol Sci 24:8488. https:\/\/doi.org\/10.3390\/ijms24108488","journal-title":"Int J Mol Sci"},{"key":"2281_CR67","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3390\/cancers15082357","volume":"15","author":"SSY Wang","year":"2023","unstructured":"Wang SSY, Jie YE, Cheng SW et al (2023) PARP inhibitors in breast and ovarian cancer. Cancers (Basel) 15:2357. https:\/\/doi.org\/10.3390\/cancers15082357","journal-title":"Cancers (Basel)"},{"key":"2281_CR68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40364-024-00653-2","volume":"12","author":"J Li","year":"2024","unstructured":"Li J, Jia Z, Dong L et al (2024) DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomark Res 12:111. https:\/\/doi.org\/10.1186\/s40364-024-00653-2","journal-title":"Biomark Res"},{"key":"2281_CR69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/cco-19-230","volume":"10","author":"HA Azim","year":"2021","unstructured":"Azim HA, Kassem L, Azim H Jr (2021) Integrating PARP inhibitors into the management of breast cancer: where are we? Chin Clin Oncol 10:50\u201350. https:\/\/doi.org\/10.21037\/cco-19-230","journal-title":"Chin Clin Oncol"},{"key":"2281_CR70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/bcr2566","volume":"12","author":"BP Rowe","year":"2010","unstructured":"Rowe BP, Glazer PM (2010) Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 12:203. https:\/\/doi.org\/10.1186\/bcr2566","journal-title":"Breast Cancer Res"},{"key":"2281_CR71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"L Livraghi","year":"2015","unstructured":"Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:188. https:\/\/doi.org\/10.1186\/s12916-015-0425-1","journal-title":"BMC Med"},{"key":"2281_CR72","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.3390\/cancers15143642","volume":"15","author":"S Dilmac","year":"2023","unstructured":"Dilmac S, Ozpolat B (2023) Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated breast cancer and new therapeutic approaches. Cancers (Basel) 15:3642. https:\/\/doi.org\/10.3390\/cancers15143642","journal-title":"Cancers (Basel)"},{"key":"2281_CR73","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu Z-Y, Wu N et al (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19:107. https:\/\/doi.org\/10.1186\/s12943-020-01227-0","journal-title":"Mol Cancer"},{"key":"2281_CR74","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/jcm8040435","volume":"8","author":"M Keung","year":"2019","unstructured":"Keung M, Wu Y, Vadgama J (2019) PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. J Clin Med 8:435. https:\/\/doi.org\/10.3390\/jcm8040435","journal-title":"J Clin Med"},{"key":"2281_CR75","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.7150\/jca.64205","volume":"12","author":"MJ Bou-Dargham","year":"2021","unstructured":"Bou-Dargham MJ, Draughon S, Cantrell V et al (2021) Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer 12:6949\u20136963. https:\/\/doi.org\/10.7150\/jca.64205","journal-title":"J Cancer"},{"key":"2281_CR76","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/abbs\/gmv119","volume":"48","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Rucker EB, Zhou BP (2016) Autophagy regulation in the development and treatment of breast cancer. Acta Biochim Biophys Sin (Shanghai) 48:60\u201374. https:\/\/doi.org\/10.1093\/abbs\/gmv119","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"2281_CR77","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.7150\/jca.97775","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang M, Liu M, Yang C et al (2024) Autophagy modulation in therapeutic strategy of breast cancer drug resistance. J Cancer 15:5462\u20135476. https:\/\/doi.org\/10.7150\/jca.97775","journal-title":"J Cancer"},{"key":"2281_CR78","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/biomedicines11020618","volume":"11","author":"HM Kim","year":"2023","unstructured":"Kim HM, Koo JS (2023) The role of autophagy in breast cancer metastasis. Biomedicines 11:618. https:\/\/doi.org\/10.3390\/biomedicines11020618","journal-title":"Biomedicines"},{"key":"2281_CR79","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.3390\/ijms21217836","volume":"21","author":"S Cocco","year":"2020","unstructured":"Cocco S, Leone A, Piezzo M et al (2020) Targeting autophagy in breast cancer. Int J Mol Sci 21:7836. https:\/\/doi.org\/10.3390\/ijms21217836","journal-title":"Int J Mol Sci"},{"key":"2281_CR80","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12935-024-03579-9","volume":"24","author":"Y Fei","year":"2024","unstructured":"Fei Y, Yan X, Liang M et al (2024) Lysosomal gene ATP6AP1 promotes doxorubicin resistance via up-regulating autophagic flux in breast cancer. Cancer Cell Int 24:394. https:\/\/doi.org\/10.1186\/s12935-024-03579-9","journal-title":"Cancer Cell Int"},{"key":"2281_CR81","doi-asserted-by":"publisher","first-page":"2358648","DOI":"10.1080\/27694127.2024.2358648","volume":"3","author":"S Raza","year":"2024","unstructured":"Raza S, Siddiqui JA, Srivastava A et al (2024) Autophagy as a therapeutic target in breast tumors: the cancer stem cell perspective. Autophagy Rep 3:2358648. https:\/\/doi.org\/10.1080\/27694127.2024.2358648","journal-title":"Autophagy Rep"},{"key":"2281_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 Blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6:39. https:\/\/doi.org\/10.1186\/s40425-018-0349-3","journal-title":"J Immunother Cancer"},{"key":"2281_CR83","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J et al (2024) PD-1\/PD-L1 immune checkpoint Blockade in breast cancer: research insights and sensitization strategies. Mol Cancer 23:266. https:\/\/doi.org\/10.1186\/s12943-024-02176-8","journal-title":"Mol Cancer"},{"key":"2281_CR84","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W et al (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Experimental Clin Cancer Res 40:184. https:\/\/doi.org\/10.1186\/s13046-021-01987-7","journal-title":"J Experimental Clin Cancer Res"},{"key":"2281_CR85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y et al (2023) Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer 22:105. https:\/\/doi.org\/10.1186\/s12943-023-01805-y","journal-title":"Mol Cancer"},{"key":"2281_CR86","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","volume":"10","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Navarro V, Matikas A et al (2024) Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer. JAMA Oncol 10:1331. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3456","journal-title":"JAMA Oncol"},{"key":"2281_CR87","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X (2024) A comprehensive review of HER2 in cancer biology and therapeutics. Genes (Basel) 15:903. https:\/\/doi.org\/10.3390\/genes15070903","journal-title":"Genes (Basel)"},{"key":"2281_CR88","doi-asserted-by":"publisher","first-page":"1513836","DOI":"10.3389\/fmed.2025.1513836","volume":"12","author":"H Luo","year":"2025","unstructured":"Luo H, Sun Y, Xu T (2025) Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer. Front Med (Lausanne) 12:1513836. https:\/\/doi.org\/10.3389\/fmed.2025.1513836","journal-title":"Front Med (Lausanne)"},{"key":"2281_CR89","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s12282-025-01779-3","volume":"32","author":"X Li","year":"2025","unstructured":"Li X, Huang T (2025) Advances in the intrinsic signaling pathway interactions and clinical translation of HR+\/HER2\u2009+\u2009breast cancer. Breast Cancer 32:1216\u20131243. https:\/\/doi.org\/10.1007\/s12282-025-01779-3","journal-title":"Breast Cancer"},{"key":"2281_CR90","doi-asserted-by":"publisher","first-page":"97","DOI":"10.31557\/apjcb.2024.9.1.97-103","volume":"9","author":"MS Gamde","year":"2024","unstructured":"Gamde MS, Ogenyi OD (2024) Angiogenesis in breast cancer: A review. Asian Pac J Cancer Biology 9:97\u2013103. https:\/\/doi.org\/10.31557\/apjcb.2024.9.1.97-103","journal-title":"Asian Pac J Cancer Biology"},{"key":"2281_CR91","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00432-024-05714-5","volume":"150","author":"Y Kang","year":"2024","unstructured":"Kang Y, Li H, Liu Y, Li Z (2024) Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors. J Cancer Res Clin Oncol 150:221. https:\/\/doi.org\/10.1007\/s00432-024-05714-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"2281_CR92","doi-asserted-by":"publisher","first-page":"838133","DOI":"10.3389\/fphar.2022.838133","volume":"13","author":"NM Ayoub","year":"2022","unstructured":"Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE (2022) Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Front Pharmacol 13:838133. https:\/\/doi.org\/10.3389\/fphar.2022.838133","journal-title":"Front Pharmacol"},{"key":"2281_CR93","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/cancers17071126","volume":"17","author":"E Chitoran","year":"2025","unstructured":"Chitoran E, Rotaru V, Stefan D-C et al (2025) Blocking tumoral angiogenesis VEGF\/VEGFR pathway: Bevacizumab\u201420 years of therapeutic success and controversy. Cancers (Basel) 17:1126. https:\/\/doi.org\/10.3390\/cancers17071126","journal-title":"Cancers (Basel)"},{"key":"2281_CR94","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"2281_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40364-021-00312-w","volume":"9","author":"W Chen","year":"2021","unstructured":"Chen W, Shen L, Jiang J et al (2021) Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 9:59. https:\/\/doi.org\/10.1186\/s40364-021-00312-w","journal-title":"Biomark Res"},{"key":"2281_CR96","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s13287-023-03571-6","volume":"14","author":"R Farahzadi","year":"2023","unstructured":"Farahzadi R, Valipour B, Fathi E et al (2023) Oxidative stress regulation and related metabolic pathways in epithelial\u2013mesenchymal transition of breast cancer stem cells. Stem Cell Res Ther 14:342. https:\/\/doi.org\/10.1186\/s13287-023-03571-6","journal-title":"Stem Cell Res Ther"},{"key":"2281_CR97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X (2022) The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol 15:129. https:\/\/doi.org\/10.1186\/s13045-022-01347-8","journal-title":"J Hematol Oncol"},{"key":"2281_CR98","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-024-01932-0","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Qin C, Dewanjee S et al (2024) Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance. Mol Cancer 23:18. https:\/\/doi.org\/10.1186\/s12943-024-01932-0","journal-title":"Mol Cancer"},{"key":"2281_CR99","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C et al (2024) Wnt\/\u03b2-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci 81:79. https:\/\/doi.org\/10.1007\/s00018-023-05099-7","journal-title":"Cell Mol Life Sci"},{"key":"2281_CR100","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13058-024-01827-4","volume":"26","author":"P Chaudhary","year":"2024","unstructured":"Chaudhary P, Yadav K, Lee HJ et al (2024) SiRNA treatment targeting integrin \u03b111 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression. Breast Cancer Res 26:72. https:\/\/doi.org\/10.1186\/s13058-024-01827-4","journal-title":"Breast Cancer Res"},{"key":"2281_CR101","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.3390\/molecules27227825","volume":"27","author":"R Alaaeldin","year":"2022","unstructured":"Alaaeldin R, Ali FEM, Bekhit AA et al (2022) Inhibition of NF-kB\/IL-6\/JAK2\/STAT3 pathway and Epithelial-Mesenchymal transition in breast cancer cells by Azilsartan. Molecules 27:7825. https:\/\/doi.org\/10.3390\/molecules27227825","journal-title":"Molecules"},{"key":"2281_CR102","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/antiox14010104","volume":"14","author":"R Dong","year":"2025","unstructured":"Dong R, Wang J, Guan R et al (2025) Role of oxidative stress in the Occurrence, Development, and treatment of breast cancer. Antioxidants 14:104. https:\/\/doi.org\/10.3390\/antiox14010104","journal-title":"Antioxidants"},{"key":"2281_CR103","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.3390\/cimb46050282","volume":"46","author":"LV Bel\u2019skaya","year":"2024","unstructured":"Bel\u2019skaya LV, Dyachenko EI (2024) Oxidative stress in breast cancer: A biochemical map of reactive oxygen species production. Curr Issues Mol Biol 46:4646\u20134687. https:\/\/doi.org\/10.3390\/cimb46050282","journal-title":"Curr Issues Mol Biol"},{"key":"2281_CR104","doi-asserted-by":"publisher","first-page":"1499125","DOI":"10.3389\/fonc.2024.1499125","volume":"14","author":"C Peng","year":"2024","unstructured":"Peng C, Chen Y, Jiang M (2024) Targeting ferroptosis: a promising strategy to overcome drug resistance in breast cancer. Front Oncol 14:1499125. https:\/\/doi.org\/10.3389\/fonc.2024.1499125","journal-title":"Front Oncol"},{"key":"2281_CR105","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11658-024-00560-2","volume":"29","author":"S Xiang","year":"2024","unstructured":"Xiang S, Yan W, Ren X et al (2024) Role of ferroptosis and ferroptosis-related long non\u2019coding RNA in breast cancer. Cell Mol Biol Lett 29:40. https:\/\/doi.org\/10.1186\/s11658-024-00560-2","journal-title":"Cell Mol Biol Lett"},{"key":"2281_CR106","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12943-025-02445-0","volume":"24","author":"Z Jing","year":"2025","unstructured":"Jing Z, Huang W, Mei J et al (2025) Advances in novel cell death mechanisms in breast cancer: intersecting perspectives on ferroptosis, cuproptosis, disulfidptosis, and pyroptosis. Mol Cancer 24:224. https:\/\/doi.org\/10.1186\/s12943-025-02445-0","journal-title":"Mol Cancer"},{"key":"2281_CR107","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12951-025-03569-7","volume":"23","author":"M Pei","year":"2025","unstructured":"Pei M, Guan X, Hou X et al (2025) A GSH-consuming polymeric nanoparticles drives ferroptosis amplification and combines chemotherapy to amplify breast cancer treatment. J Nanobiotechnol 23:497. https:\/\/doi.org\/10.1186\/s12951-025-03569-7","journal-title":"J Nanobiotechnol"},{"key":"2281_CR108","doi-asserted-by":"publisher","first-page":"111869","DOI":"10.1016\/j.cellsig.2025.111869","volume":"134","author":"B Wang","year":"2025","unstructured":"Wang B, Liu Z-H, Li J-J et al (2025) Role of ferroptosis in breast cancer: molecular mechanisms and therapeutic interventions. Cell Signal 134:111869. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111869","journal-title":"Cell Signal"},{"key":"2281_CR109","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS et al (2023) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10:1367\u20131401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007","journal-title":"Genes Dis"},{"key":"2281_CR110","doi-asserted-by":"publisher","first-page":"107068","DOI":"10.1016\/j.jddst.2025.107068","volume":"110","author":"S Bhattacharya","year":"2025","unstructured":"Bhattacharya S, Chatterjee D, Datta A (2025) Mesoporous silica nanoparticles in smart drug delivery and SiRNA precision therapy for cancer: nanomedicine\u2019s new frontier. J Drug Deliv Sci Technol 110:107068. https:\/\/doi.org\/10.1016\/j.jddst.2025.107068","journal-title":"J Drug Deliv Sci Technol"},{"key":"2281_CR111","doi-asserted-by":"publisher","first-page":"1405491","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z (2024) Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol 14:1405491. https:\/\/doi.org\/10.3389\/fonc.2024.1405491","journal-title":"Front Oncol"},{"key":"2281_CR112","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/cancers16061139","volume":"16","author":"A Sofianidi","year":"2024","unstructured":"Sofianidi A, Dumbrava EE, Syrigos KN, Nasrazadani A (2024) Triple-Negative breast cancer and emerging therapeutic strategies: ATR and CHK1\/2 as promising targets. Cancers (Basel) 16:1139. https:\/\/doi.org\/10.3390\/cancers16061139","journal-title":"Cancers (Basel)"},{"key":"2281_CR113","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA (2022) Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer 8:95. https:\/\/doi.org\/10.1038\/s41523-022-00468-0","journal-title":"NPJ Breast Cancer"},{"key":"2281_CR114","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.amsu.2020.06.016","volume":"56","author":"M Riis","year":"2020","unstructured":"Riis M (2020) Modern surgical treatment of breast cancer. Annals Med Surg 56:95\u2013107. https:\/\/doi.org\/10.1016\/j.amsu.2020.06.016","journal-title":"Annals Med Surg"},{"key":"2281_CR115","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/annonc\/mdn748","volume":"20","author":"G Frasci","year":"2009","unstructured":"Frasci G, Comella P, Rinaldo M et al (2009) Preoperative weekly cisplatin\u2013epirubicin\u2013paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 20:1185\u20131192. https:\/\/doi.org\/10.1093\/annonc\/mdn748","journal-title":"Ann Oncol"},{"key":"2281_CR116","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/jpm13050865","volume":"13","author":"A Di Leone","year":"2023","unstructured":"Di Leone A, Franco A, Zotta F et al (2023) Local treatment of Triple-Negative breast cancer: is mastectomy superior to breast-Conserving surgery? J Pers Med 13:865. https:\/\/doi.org\/10.3390\/jpm13050865","journal-title":"J Pers Med"},{"key":"2281_CR117","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/cncr.24094","volume":"115","author":"GM Freedman","year":"2009","unstructured":"Freedman GM, Anderson PR, Li T, Nicolaou N (2009) Locoregional recurrence of triple-negative breast cancer after breast\u2010conserving surgery and radiation. Cancer 115:946\u2013951. https:\/\/doi.org\/10.1002\/cncr.24094","journal-title":"Cancer"},{"key":"2281_CR118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y et al (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0","journal-title":"J Hematol Oncol"},{"key":"2281_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43440-024-00662-w","volume":"77","author":"YA Abdelrady","year":"2025","unstructured":"Abdelrady YA, Thabet HS, Sayed AM (2025) The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing. Pharmacol Rep 77:1\u201320. https:\/\/doi.org\/10.1007\/s43440-024-00662-w","journal-title":"Pharmacol Rep"},{"key":"2281_CR120","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0976-500X.136098","volume":"5","author":"R Maiti","year":"2014","unstructured":"Maiti R (2014) Metronomic chemotherapy. J Pharmacol Pharmacother 5:186\u2013192. https:\/\/doi.org\/10.4103\/0976-500X.136098","journal-title":"J Pharmacol Pharmacother"},{"key":"2281_CR121","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clbc.2024.11.003","volume":"25","author":"E Battaiotto","year":"2025","unstructured":"Battaiotto E, d\u2019Ambrosio S, Trapani D, Curigliano G (2025) Metronomic chemotherapy in breast cancer as a strategy to deliver more sustainable and less toxic treatments: time to debunk the myth? Clin Breast Cancer 25:85\u201395e18. https:\/\/doi.org\/10.1016\/j.clbc.2024.11.003","journal-title":"Clin Breast Cancer"},{"key":"2281_CR122","doi-asserted-by":"publisher","unstructured":"Han HS, Vikas P, Costa RLB et al (2023) Early-stage triple-negative breast cancer journey: beginning, end, and everything in between. American society of clinical. https:\/\/doi.org\/10.1200\/EDBK_390464. Oncology Educational Book","DOI":"10.1200\/EDBK_390464"},{"key":"2281_CR123","unstructured":"http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm358301.pdf"},{"key":"2281_CR124","first-page":"167","volume":"10","author":"SE Caulfield","year":"2019","unstructured":"Caulfield SE, Davis CC, Byers KF (2019) Olaparib: A novel therapy for metastatic breast cancer in patients with a BRCA1\/2 mutation. J Adv Pract Oncol 10:167\u2013174","journal-title":"J Adv Pract Oncol"},{"key":"2281_CR125","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO (2023) Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics 15:1796. https:\/\/doi.org\/10.3390\/pharmaceutics15071796","journal-title":"Pharmaceutics"},{"key":"2281_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2014.00024","author":"R Baskar","year":"2014","unstructured":"Baskar R, Dai J, Wenlong N et al (2014) Biological response of cancer cells to radiation treatment. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2014.00024. 1:","journal-title":"Front Mol Biosci"},{"key":"2281_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1061186X.2024.2373306","volume":"32","author":"D Chatterjee","year":"2024","unstructured":"Chatterjee D, Bhattacharya S, Kumari L, Datta A (2024) Aptamers: ushering in new hopes in targeted glioblastoma therapy. J Drug Target 32:1\u201324 https:\/\/doi.org\/10.1080\/1061186X.2024.2373306","journal-title":"J Drug Target"},{"key":"2281_CR128","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ijrobp.2024.01.206","volume":"119","author":"CH Stokkev\u00e5g","year":"2024","unstructured":"Stokkev\u00e5g CH, Journy N, Vogelius IR et al (2024) Radiation therapy technology advances and mitigation of subsequent neoplasms in childhood cancer survivors. Int J Radiation Oncology*Biology*Physics 119:681\u2013696. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.206","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"2281_CR129","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.2165\/11538150-000000000-00000","volume":"70","author":"S Dawood","year":"2010","unstructured":"Dawood S (2010) Triple-Negative breast cancer. Drugs 70:2247\u20132258. https:\/\/doi.org\/10.2165\/11538150-000000000-00000","journal-title":"Drugs"},{"key":"2281_CR130","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/ijerph17062078","volume":"17","author":"MA Medina","year":"2020","unstructured":"Medina MA, Oza G, Sharma A et al (2020) Triple-Negative breast cancer: A review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health 17:2078. https:\/\/doi.org\/10.3390\/ijerph17062078","journal-title":"Int J Environ Res Public Health"},{"key":"2281_CR131","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10549-011-1495-1","volume":"128","author":"JE Panoff","year":"2011","unstructured":"Panoff JE, Hurley J, Takita C et al (2011) Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 128:899\u2013906. https:\/\/doi.org\/10.1007\/s10549-011-1495-1","journal-title":"Breast Cancer Res Treat"},{"key":"2281_CR132","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4143\/crt.2023.846","volume":"55","author":"EY Lee","year":"2023","unstructured":"Lee EY, Lee D-W, Lee K-H, Im S-A (2023) Recent developments in the therapeutic landscape of advanced or metastatic hormone Receptor\u2013Positive breast cancer. Cancer Res Treat 55:1065\u20131076. https:\/\/doi.org\/10.4143\/crt.2023.846","journal-title":"Cancer Res Treat"},{"key":"2281_CR133","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fonc.2019.00510","volume":"9","author":"R El Sayed","year":"2019","unstructured":"El Sayed R, El Jamal L, El Iskandarani S et al (2019) Endocrine and targeted therapy for Hormone-Receptor-Positive, HER2-Negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Front Oncol 9:510. https:\/\/doi.org\/10.3389\/fonc.2019.00510","journal-title":"Front Oncol"},{"key":"2281_CR134","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1503\/cjs.006211","volume":"57","author":"R Simon","year":"2014","unstructured":"Simon R, Latreille J, Matte C et al (2014) Adherence to adjuvant endocrine therapy in Estrogen receptor\u2013positive breast cancer patients with regular follow-up. Can J Surg 57:26\u201332. https:\/\/doi.org\/10.1503\/cjs.006211","journal-title":"Can J Surg"},{"key":"2281_CR135","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.3390\/cancers14205132","volume":"14","author":"CJ Curtaz","year":"2022","unstructured":"Curtaz CJ, Kiesel L, Meybohm P et al (2022) Anti-Hormonal therapy in breast cancer and its effect on the Blood-Brain barrier. Cancers (Basel) 14:5132. https:\/\/doi.org\/10.3390\/cancers14205132","journal-title":"Cancers (Basel)"},{"key":"2281_CR136","unstructured":"https:\/\/www.breastcancer.org\/treatment\/hormonal-therapy"},{"key":"2281_CR137","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s10495-025-02123-y","volume":"30","author":"N Ghosh","year":"2025","unstructured":"Ghosh N, Chatterjee D, Datta A (2025) Tumor heterogeneity and resistance in glioblastoma: the role of stem cells. Apoptosis 30:1695\u20131729. https:\/\/doi.org\/10.1007\/s10495-025-02123-y","journal-title":"Apoptosis"},{"key":"2281_CR138","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","volume":"45","author":"E Hamilton","year":"2016","unstructured":"Hamilton E, Infante JR (2016) Targeting CDK4\/6 in patients with cancer. Cancer Treat Rev 45:129\u2013138. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.002","journal-title":"Cancer Treat Rev"},{"key":"2281_CR139","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431\u20132442. https:\/\/doi.org\/10.1056\/NEJMra023246","journal-title":"N Engl J Med"},{"key":"2281_CR140","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107\u2013118. https:\/\/doi.org\/10.1056\/NEJMoa1404037","journal-title":"N Engl J Med"},{"key":"2281_CR141","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Kaklamani VG, Neven P et al (2022) Elacestrant (oral selective Estrogen receptor degrader) versus standard endocrine therapy for Estrogen receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40:3246\u20133256. https:\/\/doi.org\/10.1200\/JCO.22.00338","journal-title":"J Clin Oncol"},{"key":"2281_CR142","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant Tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805\u2013816. https:\/\/doi.org\/10.1016\/S0140-6736(12)61963-1","journal-title":"Lancet"},{"key":"2281_CR143","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.117.195677","volume":"59","author":"M\u00d8 Fosb\u00f8l","year":"2018","unstructured":"Fosb\u00f8l M\u00d8, Petersen PM, Kjaer A, Mortensen J (2018) 223 Ra therapy of advanced metastatic Castration-Resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity. J Nucl Med 59:596\u2013602. https:\/\/doi.org\/10.2967\/jnumed.117.195677","journal-title":"J Nucl Med"},{"key":"2281_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006019.pub2","author":"S Kumar","year":"2006","unstructured":"Kumar S, Shelley M, Harrison C et al (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Reviews 2010. https:\/\/doi.org\/10.1002\/14651858.CD006019.pub2","journal-title":"Cochrane Database Syst Reviews 2010"},{"key":"2281_CR145","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194\u20131220. https:\/\/doi.org\/10.1093\/annonc\/mdz173","journal-title":"Ann Oncol"},{"key":"2281_CR146","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cncr.28469","volume":"120","author":"MC Fingeret","year":"2014","unstructured":"Fingeret MC, Teo I, Epner DE (2014) Managing body image difficulties of adult cancer patients: lessons from available research. Cancer 120:633\u2013641. https:\/\/doi.org\/10.1002\/cncr.28469","journal-title":"Cancer"},{"key":"2281_CR147","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"},{"key":"2281_CR148","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1200\/JCO.2013.52.2284","volume":"32","author":"R Jagsi","year":"2014","unstructured":"Jagsi R, Jiang J, Momoh AO et al (2014) Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the united States. J Clin Oncol 32:919\u2013926. https:\/\/doi.org\/10.1200\/JCO.2013.52.2284","journal-title":"J Clin Oncol"},{"key":"2281_CR149","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5999\/aps.2015.42.5.532","volume":"42","author":"H Headon","year":"2015","unstructured":"Headon H, Kasem A, Mokbel K (2015) Capsular contracture after breast augmentation: an update for clinical practice. Arch Plast Surg 42:532\u2013543. https:\/\/doi.org\/10.5999\/aps.2015.42.5.532","journal-title":"Arch Plast Surg"},{"key":"2281_CR150","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamasurg.2020.4124","volume":"155","author":"K-T Lee","year":"2020","unstructured":"Lee K-T, Kim S, Jeon B-J et al (2020) Association of the implant surface texture used in reconstruction with breast cancer recurrence. JAMA Surg 155:1132. https:\/\/doi.org\/10.1001\/jamasurg.2020.4124","journal-title":"JAMA Surg"},{"key":"2281_CR151","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436\u2013444. https:\/\/doi.org\/10.1038\/nature07205","journal-title":"Nature"},{"key":"2281_CR152","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/PRS.0000000000002494","volume":"138","author":"B Chaput","year":"2016","unstructured":"Chaput B, Bertheuil N, Escubes M et al (2016) Mechanically isolated stromal vascular fraction provides a valid and useful collagenase-free alternative technique: a comparative study. Plast Reconstr Surg 138:807\u2013819. https:\/\/doi.org\/10.1097\/PRS.0000000000002494","journal-title":"Plast Reconstr Surg"},{"key":"2281_CR153","doi-asserted-by":"publisher","unstructured":"Jallah JK, Dweh TJ, Anjankar A, Palma O (2023) A review of the advancements in targeted therapies for breast cancer. Cureus. https:\/\/doi.org\/10.7759\/cureus.47847","DOI":"10.7759\/cureus.47847"},{"key":"2281_CR154","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.3390\/cancers17203288","volume":"17","author":"H Bischoff","year":"2025","unstructured":"Bischoff H, Somme L, Petit T (2025) Optimizing Post-Neoadjuvant treatment in early Triple-Negative breast cancer. Cancers (Basel) 17:3288. https:\/\/doi.org\/10.3390\/cancers17203288","journal-title":"Cancers (Basel)"},{"key":"2281_CR155","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751\u2013760. https:\/\/doi.org\/10.1038\/nnano.2007.387","journal-title":"Nat Nanotechnol"},{"key":"2281_CR156","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle Albumin-Bound Paclitaxel compared with polyethylated castor Oil\u2013Based Paclitaxel in women with breast cancer. J Clin Oncol 23:7794\u20137803. https:\/\/doi.org\/10.1200\/JCO.2005.04.937","journal-title":"J Clin Oncol"},{"key":"2281_CR157","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.addr.2021.03.018","volume":"173","author":"P Boix-Montesinos","year":"2021","unstructured":"Boix-Montesinos P, Soriano-Teruel PM, Armi\u00f1\u00e1n A et al (2021) The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev 173:306\u2013330. https:\/\/doi.org\/10.1016\/j.addr.2021.03.018","journal-title":"Adv Drug Deliv Rev"},{"key":"2281_CR158","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68351","author":"A Rai","year":"2024","unstructured":"Rai A, Deshpande SG, Vaidya A, Shinde RK (2024) Advancements in immunotherapy for breast cancer: mechanisms, efficacy, and future directions. Cureus. https:\/\/doi.org\/10.7759\/cureus.68351","journal-title":"Cureus"},{"key":"2281_CR159","doi-asserted-by":"publisher","first-page":"103915","DOI":"10.1016\/j.critrevonc.2023.103915","volume":"183","author":"A Behl","year":"2023","unstructured":"Behl A, Wani ZA, Das NN et al (2023) Monoclonal antibodies in breast cancer: A critical appraisal. Crit Rev Oncol Hematol 183:103915. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103915","journal-title":"Crit Rev Oncol Hematol"},{"key":"2281_CR160","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab \u2014 Mechanism of action and use in clinical practice. N Engl J Med 357:39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186","journal-title":"N Engl J Med"},{"key":"2281_CR161","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early Triple-Negative breast cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"2281_CR162","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17:717\u2013726. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3","journal-title":"Lancet Oncol"},{"key":"2281_CR163","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D et al (2019) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30:405\u2013411. https:\/\/doi.org\/10.1093\/annonc\/mdy518","journal-title":"Ann Oncol"},{"key":"2281_CR164","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW et al (2022) Pembrolizumab plus chemotherapy in advanced Triple-Negative breast cancer. N Engl J Med 387:217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"2281_CR165","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH et al (2021) First-line Atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 32:983\u2013993. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.355","journal-title":"Ann Oncol"},{"key":"2281_CR166","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ (2020) Novel HER2\u2013targeted therapies for HER2\u2013positive metastatic breast cancer. Cancer 126:4278\u20134288. https:\/\/doi.org\/10.1002\/cncr.33102","journal-title":"Cancer"},{"key":"2281_CR167","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers15071987","volume":"15","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci R (2023) Emerging targeted therapies for HER2-Positive breast cancer. Cancers (Basel) 15:1987. https:\/\/doi.org\/10.3390\/cancers15071987","journal-title":"Cancers (Basel)"},{"key":"2281_CR168","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","volume":"484","author":"M Ivanova","year":"2024","unstructured":"Ivanova M, Porta FM, D\u2019Ercole M et al (2024) Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch 484:3\u201314. https:\/\/doi.org\/10.1007\/s00428-023-03656-w","journal-title":"Virchows Arch"},{"key":"2281_CR169","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","volume":"6","author":"NL Henry","year":"2012","unstructured":"Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6:140\u2013146. https:\/\/doi.org\/10.1016\/j.molonc.2012.01.010","journal-title":"Mol Oncol"},{"key":"2281_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/906082","volume":"2010","author":"M De Bock","year":"2010","unstructured":"De Bock M, de Seny D, Meuwis M-A et al (2010) Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol 2010:1\u201315. https:\/\/doi.org\/10.1155\/2010\/906082","journal-title":"J Biomed Biotechnol"},{"key":"2281_CR171","doi-asserted-by":"publisher","first-page":"112730","DOI":"10.1016\/j.bios.2020.112730","volume":"171","author":"X Zhu","year":"2021","unstructured":"Zhu X, Zhang Y, Liu M, Liu Y (2021) 2D titanium carbide MXenes as emerging optical biosensing platforms. Biosens Bioelectron 171:112730. https:\/\/doi.org\/10.1016\/j.bios.2020.112730","journal-title":"Biosens Bioelectron"},{"key":"2281_CR172","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/cmmi.499","volume":"7","author":"NL Adolphi","year":"2012","unstructured":"Adolphi NL, Butler KS, Lovato DM et al (2012) Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID\u2010detected magnetic relaxometry and MRI. Contrast Media Mol Imaging 7:308\u2013319. https:\/\/doi.org\/10.1002\/cmmi.499","journal-title":"Contrast Media Mol Imaging"},{"key":"2281_CR173","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1007\/s12274-024-6471-2","volume":"17","author":"L Ye","year":"2024","unstructured":"Ye L, Xu X, Qu A et al (2024) Quantitative assessment of the breast cancer marker HER2 using a gold nanoparticle-based lateral flow immunoassay. Nano Res 17:5452\u20135460. https:\/\/doi.org\/10.1007\/s12274-024-6471-2","journal-title":"Nano Res"},{"key":"2281_CR174","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41467-023-37403-1","volume":"14","author":"H Shin","year":"2023","unstructured":"Shin H, Choi BH, Shim O et al (2023) Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers. Nat Commun 14:1644. https:\/\/doi.org\/10.1038\/s41467-023-37403-1","journal-title":"Nat Commun"},{"key":"2281_CR175","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/bios13010080","volume":"13","author":"A Mohammadpour-Haratbar","year":"2023","unstructured":"Mohammadpour-Haratbar A, Boraei SBA, Zare Y et al (2023) Graphene-based electrochemical biosensors for breast cancer detection. Biosens (Basel) 13:80. https:\/\/doi.org\/10.3390\/bios13010080","journal-title":"Biosens (Basel)"},{"key":"2281_CR176","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/nano14171424","volume":"14","author":"D Kunachowicz","year":"2024","unstructured":"Kunachowicz D, K\u0142osowska K, Sobczak N, Kepinska M (2024) Applicability of quantum Dots in breast cancer diagnostic and therapeutic Modalities\u2014A State-of-the-Art review. Nanomaterials 14:1424. https:\/\/doi.org\/10.3390\/nano14171424","journal-title":"Nanomaterials"},{"key":"2281_CR177","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.3390\/ma17092152","volume":"17","author":"H Omidian","year":"2024","unstructured":"Omidian H, Wilson RL, Cubeddu LX (2024) Quantum Dot research in breast cancer: challenges and prospects. Materials 17:2152. https:\/\/doi.org\/10.3390\/ma17092152","journal-title":"Materials"},{"key":"2281_CR178","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00604-025-07048-6","volume":"192","author":"V Solovicov\u00e1","year":"2025","unstructured":"Solovicov\u00e1 V, \u010eatkov\u00e1 A, Bert\u00f3k T et al (2025) Advances in magnetic affinity-based isolation\/detection of exosomes for robust diagnostics. Microchim Acta 192:206. https:\/\/doi.org\/10.1007\/s00604-025-07048-6","journal-title":"Microchim Acta"},{"key":"2281_CR179","doi-asserted-by":"publisher","first-page":"37130","DOI":"10.1021\/acsami.3c05039","volume":"15","author":"X Su","year":"2023","unstructured":"Su X, Xie Y, Liu X et al (2023) Absolute quantification of serum exosomes in patients with an SERS-Lateral flow strip biosensor for noninvasive clinical cancer diagnosis. ACS Appl Mater Interfaces 15:37130\u201337142. https:\/\/doi.org\/10.1021\/acsami.3c05039","journal-title":"ACS Appl Mater Interfaces"},{"key":"2281_CR180","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13036-025-00512-0","volume":"19","author":"C Cabeza","year":"2025","unstructured":"Cabeza C, Rojas F, Lobos-Gonz\u00e1lez L et al (2025) Capture and detection of extracellular vesicles derived from human breast cancer cells using a 3D self-assembled nanostructured SiO2 microfluidic chip. J Biol Eng 19:71. https:\/\/doi.org\/10.1186\/s13036-025-00512-0","journal-title":"J Biol Eng"},{"key":"2281_CR181","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12951-024-02863-0","volume":"22","author":"H Tang","year":"2024","unstructured":"Tang H, Yu D, Zhang J et al (2024) The new advance of exosome-based liquid biopsy for cancer diagnosis. J Nanobiotechnol 22:610. https:\/\/doi.org\/10.1186\/s12951-024-02863-0","journal-title":"J Nanobiotechnol"},{"key":"2281_CR182","doi-asserted-by":"publisher","first-page":"1399441","DOI":"10.3389\/fsens.2024.1399441","volume":"5","author":"O Gamal","year":"2024","unstructured":"Gamal O, Eldin MH, Refaat AA, Hassan RYA (2024) Advances in nanocomposites-based electrochemical biosensors for the early diagnosis of breast cancer. Front Sens 5:1399441. https:\/\/doi.org\/10.3389\/fsens.2024.1399441","journal-title":"Front Sens"},{"key":"2281_CR183","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/bios15070447","volume":"15","author":"ME Khosroshahi","year":"2025","unstructured":"Khosroshahi ME, Gaoiran C, Umashanker V et al (2025) Dual-Oriented targeted nanostructured SERS Label-Free immunosensor for Detection, Quantification, and analysis of breast cancer biomarker concentrations in blood serum. Biosens (Basel) 15:447. https:\/\/doi.org\/10.3390\/bios15070447","journal-title":"Biosens (Basel)"},{"key":"2281_CR184","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04482803?tab=results"},{"key":"2281_CR185","doi-asserted-by":"publisher","first-page":"023501","DOI":"10.1088\/1468-6996\/16\/2\/023501","volume":"16","author":"W Wu","year":"2015","unstructured":"Wu W, Wu Z, Yu T et al (2015) Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater 16:023501. https:\/\/doi.org\/10.1088\/1468-6996\/16\/2\/023501","journal-title":"Sci Technol Adv Mater"},{"key":"2281_CR186","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.nantod.2018.03.002","volume":"21","author":"BD Trump","year":"2018","unstructured":"Trump BD, Hristozov D, Malloy T, Linkov I (2018) Risk associated with engineered nanomaterials: different tools for different ways to govern. Nano Today 21:9\u201313. https:\/\/doi.org\/10.1016\/j.nantod.2018.03.002","journal-title":"Nano Today"},{"key":"2281_CR187","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.addr.2017.08.003","volume":"128","author":"D Liu","year":"2018","unstructured":"Liu D, Zhang H, Fontana F et al (2018) Current developments and applications of microfluidic technology toward clinical translation of nanomedicines. Adv Drug Deliv Rev 128:54\u201383. https:\/\/doi.org\/10.1016\/j.addr.2017.08.003","journal-title":"Adv Drug Deliv Rev"},{"key":"2281_CR188","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/ijms22094673","volume":"22","author":"V Gote","year":"2021","unstructured":"Gote V, Nookala AR, Bolla PK, Pal D (2021) Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue. Int J Mol Sci 22:4673. https:\/\/doi.org\/10.3390\/ijms22094673","journal-title":"Int J Mol Sci"},{"key":"2281_CR189","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3390\/cancers15112906","volume":"15","author":"R Dissanayake","year":"2023","unstructured":"Dissanayake R, Towner R, Ahmed M (2023) Metastatic breast cancer: review of emerging nanotherapeutics. Cancers (Basel) 15:2906. https:\/\/doi.org\/10.3390\/cancers15112906","journal-title":"Cancers (Basel)"},{"key":"2281_CR190","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1039\/D1BM00558H","volume":"9","author":"R Xie","year":"2021","unstructured":"Xie R, Wang Y, Gong S (2021) External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR\u2013Cas genome editors. Biomater Sci 9:6012\u20136022. https:\/\/doi.org\/10.1039\/D1BM00558H","journal-title":"Biomater Sci"},{"key":"2281_CR191","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/cancers15041023","volume":"15","author":"VP Chavda","year":"2023","unstructured":"Chavda VP, Nalla LV, Balar P et al (2023) Advanced Phytochemical-Based nanocarrier systems for the treatment of breast cancer. Cancers (Basel) 15:1023. https:\/\/doi.org\/10.3390\/cancers15041023","journal-title":"Cancers (Basel)"},{"key":"2281_CR192","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12672-024-01239-y","volume":"15","author":"A Samantaray","year":"2024","unstructured":"Samantaray A, Pradhan D, Nayak NR et al (2024) Nanoquercetin based nanoformulations for triple negative breast cancer therapy and its role in overcoming drug resistance. Discover Oncol 15:452. https:\/\/doi.org\/10.1007\/s12672-024-01239-y","journal-title":"Discover Oncol"},{"key":"2281_CR193","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1039\/C8BM01530A","volume":"7","author":"Y Song","year":"2019","unstructured":"Song Y, Sheng Z, Xu Y et al (2019) Magnetic liposomal Emodin composite with enhanced killing efficiency against breast cancer. Biomater Sci 7:867\u2013875. https:\/\/doi.org\/10.1039\/C8BM01530A","journal-title":"Biomater Sci"},{"key":"2281_CR194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/456409","volume":"2013","author":"J Lao","year":"2013","unstructured":"Lao J, Madani J, Pu\u00e9rtolas T et al (2013) Liposomal doxorubicin in the treatment of breast cancer patients: A review. J Drug Deliv 2013:1\u201312. https:\/\/doi.org\/10.1155\/2013\/456409","journal-title":"J Drug Deliv"},{"key":"2281_CR195","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00280-015-2833-5","volume":"76","author":"N Chen","year":"2015","unstructured":"Chen N, Brachmann C, Liu X et al (2015) Albumin-bound nanoparticle (nab) Paclitaxel exhibits enhanced Paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol 76:699\u2013712. https:\/\/doi.org\/10.1007\/s00280-015-2833-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"2281_CR196","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11095-019-2673-9","volume":"36","author":"K Sztandera","year":"2019","unstructured":"Sztandera K, Dzia\u0142ak P, Marcinkowska M et al (2019) Sugar modification enhances cytotoxic activity of PAMAM-Doxorubicin conjugate in Glucose-Deprived MCF-7 Cells \u2013 Possible role of GLUT1 transporter. Pharm Res 36:140. https:\/\/doi.org\/10.1007\/s11095-019-2673-9","journal-title":"Pharm Res"},{"key":"2281_CR197","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3390\/nano10112310","volume":"10","author":"M Salimi","year":"2020","unstructured":"Salimi M, Sarkar S, Hashemi M, Saber R (2020) Treatment of breast Cancer-Bearing BALB\/c mice with magnetic hyperthermia using dendrimer functionalized Iron-Oxide nanoparticles. Nanomaterials 10:2310. https:\/\/doi.org\/10.3390\/nano10112310","journal-title":"Nanomaterials"},{"key":"2281_CR198","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11095-019-2683-7","volume":"36","author":"M Marcinkowska","year":"2019","unstructured":"Marcinkowska M, Stanczyk M, Janaszewska A et al (2019) Multicomponent conjugates of anticancer drugs and monoclonal antibody with PAMAM dendrimers to increase efficacy of HER-2 positive breast cancer therapy. Pharm Res 36:154. https:\/\/doi.org\/10.1007\/s11095-019-2683-7","journal-title":"Pharm Res"},{"key":"2281_CR199","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, Trastuzumab, and docetaxel in HER2-Positive metastatic breast cancer. N Engl J Med 372:724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"2281_CR200","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.isci.2020.100979","volume":"23","author":"S Camorani","year":"2020","unstructured":"Camorani S, Granata I, Collina F et al (2020) Novel aptamers selected on living cells for specific recognition of Triple-Negative breast cancer. iScience 23:100979. https:\/\/doi.org\/10.1016\/j.isci.2020.100979","journal-title":"iScience"},{"key":"2281_CR201","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1039\/c2ra23131j","volume":"3","author":"X Cheng","year":"2013","unstructured":"Cheng X, Zhang W, Ji Y et al (2013) Revealing silver cytotoxicity using Au nanorods\/Ag shell nanostructures: disrupting cell membrane and causing apoptosis through oxidative damage. RSC Adv 3:2296. https:\/\/doi.org\/10.1039\/c2ra23131j","journal-title":"RSC Adv"},{"key":"2281_CR202","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/nano15040285","volume":"15","author":"W Graham","year":"2025","unstructured":"Graham W, Torbett-Dougherty M, Islam A et al (2025) Magnetic nanoparticles and drug delivery systems for Anti-Cancer applications: A review. Nanomaterials 15:285. https:\/\/doi.org\/10.3390\/nano15040285","journal-title":"Nanomaterials"},{"key":"2281_CR203","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1007\/s11095-015-1736-9","volume":"32","author":"Y Kato","year":"2015","unstructured":"Kato Y, Zhu W, Backer MV et al (2015) Noninvasive imaging of liposomal delivery of superparamagnetic iron oxide nanoparticles to orthotopic human breast tumor in mice. Pharm Res 32:3746\u20133755. https:\/\/doi.org\/10.1007\/s11095-015-1736-9","journal-title":"Pharm Res"},{"key":"2281_CR204","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/nano10081613","volume":"10","author":"Y Yan","year":"2020","unstructured":"Yan Y, Ding H (2020) pH-Responsive nanoparticles for cancer immunotherapy: A brief review. Nanomaterials 10:1613. https:\/\/doi.org\/10.3390\/nano10081613","journal-title":"Nanomaterials"},{"key":"2281_CR205","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.actbio.2017.11.010","volume":"66","author":"Y Liu","year":"2018","unstructured":"Liu Y, Qiao L, Zhang S et al (2018) Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater 66:310\u2013324. https:\/\/doi.org\/10.1016\/j.actbio.2017.11.010","journal-title":"Acta Biomater"},{"key":"2281_CR206","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1039\/D3NA00965C","volume":"6","author":"L Leena Panigrahi","year":"2024","unstructured":"Leena Panigrahi L, Samal P, Ranjan Sahoo S et al (2024) Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer. Nanoscale Adv 6:3699\u20133713. https:\/\/doi.org\/10.1039\/D3NA00965C","journal-title":"Nanoscale Adv"},{"key":"2281_CR207","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/jpm14070723","volume":"14","author":"JB Oehler","year":"2024","unstructured":"Oehler JB, Rajapaksha W, Albrecht H (2024) Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer. J Pers Med 14:723. https:\/\/doi.org\/10.3390\/jpm14070723","journal-title":"J Pers Med"},{"key":"2281_CR208","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.3390\/ijms23052856","volume":"23","author":"P Tagde","year":"2022","unstructured":"Tagde P, Najda A, Nagpal K et al (2022) Nanomedicine-Based delivery strategies for breast cancer treatment and management. Int J Mol Sci 23:2856. https:\/\/doi.org\/10.3390\/ijms23052856","journal-title":"Int J Mol Sci"},{"key":"2281_CR209","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1039\/D4NA00660G","volume":"6","author":"A Verma","year":"2024","unstructured":"Verma A, Patel K, Kumar A (2024) Targeting drug resistance in breast cancer: the potential of MiRNA and nanotechnology-driven delivery systems. Nanoscale Adv 6:6079\u20136095. https:\/\/doi.org\/10.1039\/D4NA00660G","journal-title":"Nanoscale Adv"},{"key":"2281_CR210","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.3390\/cancers14174123","volume":"14","author":"MM Khan","year":"2022","unstructured":"Khan MM, Torchilin VP (2022) Recent trends in Nanomedicine-Based strategies to overcome multidrug resistance in tumors. Cancers (Basel) 14:4123. https:\/\/doi.org\/10.3390\/cancers14174123","journal-title":"Cancers (Basel)"},{"key":"2281_CR211","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1186\/s12885-022-10225-y","volume":"22","author":"K Sharmni Vishnu","year":"2022","unstructured":"Sharmni Vishnu K, Win TT, Aye SN, Basavaraj AK (2022) Combined Atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. BMC Cancer 22:1139. https:\/\/doi.org\/10.1186\/s12885-022-10225-y","journal-title":"BMC Cancer"},{"key":"2281_CR212","unstructured":"https:\/\/www.mycancergenome.org\/content\/clinical_trials\/NCT03719326\/"},{"key":"2281_CR213","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.3390\/cancers13153749","volume":"13","author":"Y Si","year":"2021","unstructured":"Si Y, Zhang Y, Ngo HG et al (2021) Targeted liposomal chemotherapies to treat Triple-Negative breast cancer. Cancers (Basel) 13:3749. https:\/\/doi.org\/10.3390\/cancers13153749","journal-title":"Cancers (Basel)"},{"key":"2281_CR214","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-023-06929-9","volume":"199","author":"C Yam","year":"2023","unstructured":"Yam C, Mittendorf EA, Garber HR et al (2023) A phase II study of neoadjuvant Atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199:457\u2013469. https:\/\/doi.org\/10.1007\/s10549-023-06929-9","journal-title":"Breast Cancer Res Treat"},{"key":"2281_CR215","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1039\/C7NR09083H","volume":"10","author":"Y Li","year":"2018","unstructured":"Li Y, He D, Tu J et al (2018) The comparative effect of wrapping solid gold nanoparticles and Hollow gold nanoparticles with doxorubicin-loaded thermosensitive liposomes for cancer thermo-chemotherapy. Nanoscale 10:8628\u20138641. https:\/\/doi.org\/10.1039\/C7NR09083H","journal-title":"Nanoscale"},{"key":"2281_CR216","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.04.029","volume":"282","author":"M Dunne","year":"2018","unstructured":"Dunne M, Dou YN, Drake DM et al (2018) Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer. J Controlled Release 282:35\u201345. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.029","journal-title":"J Controlled Release"},{"key":"2281_CR217","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.biopha.2018.11.011","volume":"109","author":"MS Franco","year":"2019","unstructured":"Franco MS, Roque MC, de Barros ALB et al (2019) Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating Paclitaxel and doxorubicin in a murine breast cancer animal model. Biomed Pharmacother 109:1728\u20131739. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.011","journal-title":"Biomed Pharmacother"},{"key":"2281_CR218","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/pharmaceutics14112256","volume":"14","author":"ER Gomes","year":"2022","unstructured":"Gomes ER, Souza FR, Cassali GD et al (2022) Investigation of the antitumor activity and toxicity of Tumor-Derived exosomes fused with Long-Circulating and pH-Sensitive liposomes containing doxorubicin. Pharmaceutics 14:2256. https:\/\/doi.org\/10.3390\/pharmaceutics14112256","journal-title":"Pharmaceutics"},{"key":"2281_CR219","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.biopha.2018.09.109","volume":"108","author":"ER Gomes","year":"2018","unstructured":"Gomes ER, Novais MVM, Silva IT et al (2018) Long-circulating and fusogenic liposomes loaded with a glucoevatromonoside derivative induce potent antitumor response. Biomed Pharmacother 108:1152\u20131161. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.109","journal-title":"Biomed Pharmacother"},{"key":"2281_CR220","doi-asserted-by":"publisher","first-page":"15275","DOI":"10.3390\/ijms232315275","volume":"23","author":"I Psilopatis","year":"2022","unstructured":"Psilopatis I, Souferi-Chronopoulou E, Vrettou K et al (2022) EPH\/Ephrin-Targeting treatment in breast cancer: A new chapter in breast cancer therapy. Int J Mol Sci 23:15275. https:\/\/doi.org\/10.3390\/ijms232315275","journal-title":"Int J Mol Sci"},{"key":"2281_CR221","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cancers10110418","volume":"10","author":"L Matusewicz","year":"2018","unstructured":"Matusewicz L, Podkalicka J, Sikorski AF (2018) Immunoliposomes with Simvastatin as a potential therapeutic in treatment of breast cancer cells overexpressing HER2\u2014An in vitro study. Cancers (Basel) 10:418. https:\/\/doi.org\/10.3390\/cancers10110418","journal-title":"Cancers (Basel)"},{"key":"2281_CR222","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1039\/D0TB02894K","volume":"9","author":"G Li","year":"2021","unstructured":"Li G, Zhu N, Zhou J et al (2021) A magnetic surface-enhanced Raman scattering platform for performing successive breast cancer exosome isolation and analysis. J Mater Chem B 9:2709\u20132716. https:\/\/doi.org\/10.1039\/D0TB02894K","journal-title":"J Mater Chem B"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02281-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:26:18Z","timestamp":1774985178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":222,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02281-7","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"77"}}